Michèle Kind

Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression

Lucile Vanhersecke, Maxime Brunet, Jean‐Philippe Guégan et al. · Nature Cancer · 2021 · 515 citations · Full text

Lymphoid Neoplasia, Cancer Immunosurveillance, Pd-l1 Expression +9

Midterm Local Efficacy and Survival after Radiofrequency Ablation of Lung Tumors with Minimum Follow-up of 1 Year: Prospective Evaluation

Thierry de Baère, Jean Palussière, Anne Aupérin et al. · Radiology · 2006 · 340 citations

Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial

Antoîne Italiano, Olivier Mir, Simone Mathoulin‐Pélissier et al. · The Lancet Oncology · 2020 · 306 citations · Full text

Surgical Oncology, Advanced Ewing Sarcoma, Medicine +5

Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort

Antoîne Italiano, Alban Bessede, M. Pulido et al. · Nature Medicine · 2022 · 235 citations

Lymphoid Neoplasia, Pembrosarc Trial Cohort, Medicine +7

Pazopanib or methotrexate–vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study

Maud Toulmonde, Marina Pulido, Isabelle Ray‐Coquard et al. · The Lancet Oncology · 2019 · 193 citations · Full text

Oncology, Combination Chemotherapy, Metronomic Therapy +8